Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rodrigo E Mendes

Showing results (181-190 of 257) with videos related to

Pageof 26
Sort By:
Antimicrobial Agents and Chemotherapy|April 8, 2015
Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013Helio S Sader, Mariana Castanheira, Rodrigo E Mendes, et al.
Antimicrobial Agents and Chemotherapy|January 24, 2019
Low Prevalence of Gram-Positive Isolates Showing Elevated Lefamulin MIC Results during the SENTRY Surveillance Program for 2015-2016 and Characterization of Resistance MechanismsRodrigo E Mendes, Susanne Paukner, Timothy B Doyle, et al.
Journal of Clinical Microbiology|May 24, 2013
Streptococcus sanguinis isolate displaying a phenotype with cross-resistance to several rRNA-targeting agentsRodrigo E Mendes, Lalitagauri M Deshpande, Jihye Kim, et al.
Diagnostic Microbiology and Infectious Disease|June 30, 2014
Serotype distribution and antimicrobial susceptibility of USA Streptococcus pneumoniae isolates collected prior to and post introduction of 13-valent pneumococcal conjugate vaccineRodrigo E Mendes, Andrew J Costello, Michael R Jacobs, et al.
International Journal of Antimicrobial Agents|June 14, 2016
Tigecycline antimicrobial activity tested against clinical bacteria from Latin American medical centres: results from SENTRY Antimicrobial Surveillance Program (2011-2014)Helio S Sader, Mariana Castanheira, David J Farrell, et al.
The Pediatric Infectious Disease Journal|April 14, 2017
Ceftaroline Activity Tested Against Bacterial Isolates Causing Community-acquired Respiratory Tract Infections and Skin and Skin Structure Infections in Pediatric Patients From United States Hospitals: 2012-2014Michael A Pfaller, Rodrigo E Mendes, Mariana Castanheira, et al.
The Journal of Antimicrobial Chemotherapy|August 26, 2021
Investigation of mechanisms responsible for decreased susceptibility of aztreonam/avibactam activity in clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019Rodrigo E Mendes, Timothy B Doyle, Jennifer M Streit, et al.
International Journal of Antimicrobial Agents|May 10, 2015
Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumoniaHelio S Sader, Mariana Castanheira, Robert K Flamm, et al.
The Journal of Antimicrobial Chemotherapy|September 10, 2016
Longitudinal (2001-14) analysis of enterococci and VRE causing invasive infections in European and US hospitals, including a contemporary (2010-13) analysis of oritavancin in vitro potencyRodrigo E Mendes, Mariana Castanheira, David J Farrell, et al.
Microbial Drug Resistance (Larchmont, N.Y.)|July 21, 2017
In Vitro Activity of Telavancin Against Clinically Important Gram-Positive Pathogens from 69 U.S. Medical Centers (2015): Potency Analysis by U.S. Census DivisionsMichael A Pfaller, Helio S Sader, Robert K Flamm, et al.
Pageof 26

Showing results (181-190 of 257) with videos related to

Sort By:
Pageof 26
Antimicrobial Agents and Chemotherapy|April 8, 2015
Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013Helio S Sader, Mariana Castanheira, Rodrigo E Mendes, et al.
Antimicrobial Agents and Chemotherapy|January 24, 2019
Low Prevalence of Gram-Positive Isolates Showing Elevated Lefamulin MIC Results during the SENTRY Surveillance Program for 2015-2016 and Characterization of Resistance MechanismsRodrigo E Mendes, Susanne Paukner, Timothy B Doyle, et al.
Journal of Clinical Microbiology|May 24, 2013
Streptococcus sanguinis isolate displaying a phenotype with cross-resistance to several rRNA-targeting agentsRodrigo E Mendes, Lalitagauri M Deshpande, Jihye Kim, et al.
Diagnostic Microbiology and Infectious Disease|June 30, 2014
Serotype distribution and antimicrobial susceptibility of USA Streptococcus pneumoniae isolates collected prior to and post introduction of 13-valent pneumococcal conjugate vaccineRodrigo E Mendes, Andrew J Costello, Michael R Jacobs, et al.
International Journal of Antimicrobial Agents|June 14, 2016
Tigecycline antimicrobial activity tested against clinical bacteria from Latin American medical centres: results from SENTRY Antimicrobial Surveillance Program (2011-2014)Helio S Sader, Mariana Castanheira, David J Farrell, et al.
The Pediatric Infectious Disease Journal|April 14, 2017
Ceftaroline Activity Tested Against Bacterial Isolates Causing Community-acquired Respiratory Tract Infections and Skin and Skin Structure Infections in Pediatric Patients From United States Hospitals: 2012-2014Michael A Pfaller, Rodrigo E Mendes, Mariana Castanheira, et al.
The Journal of Antimicrobial Chemotherapy|August 26, 2021
Investigation of mechanisms responsible for decreased susceptibility of aztreonam/avibactam activity in clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019Rodrigo E Mendes, Timothy B Doyle, Jennifer M Streit, et al.
International Journal of Antimicrobial Agents|May 10, 2015
Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumoniaHelio S Sader, Mariana Castanheira, Robert K Flamm, et al.
The Journal of Antimicrobial Chemotherapy|September 10, 2016
Longitudinal (2001-14) analysis of enterococci and VRE causing invasive infections in European and US hospitals, including a contemporary (2010-13) analysis of oritavancin in vitro potencyRodrigo E Mendes, Mariana Castanheira, David J Farrell, et al.
Microbial Drug Resistance (Larchmont, N.Y.)|July 21, 2017
In Vitro Activity of Telavancin Against Clinically Important Gram-Positive Pathogens from 69 U.S. Medical Centers (2015): Potency Analysis by U.S. Census DivisionsMichael A Pfaller, Helio S Sader, Robert K Flamm, et al.
Pageof 26